ð åèçïŒé«åž«åè / PGY OSCEïŒ
ð Cram Sheet
ð¥ é« yield 10
- UGIB vs LGIB (Treitz ligament)
- UGIB peptic ulcer 50%
- Variceal mortality 20-30%
- Cirrhotic UGIB â ceftriaxone (reduce SBP, mortality)
- Octreotide / terlipressin for variceal
- Hgb < 7 transfuse (< 8 cardiac, > 9 variceal)
- Glasgow-Blatchford for UGIB risk
- Heyde syndrome = AS + GI angiodysplasia
- Diverticular bleed = LGIB è人æåžž
- Reverse anticoagulation: idarucizumab (dabigatran), andexanet (factor Xa)
ð¢ å¿
è
| Hgb transfuse general |
< 7 |
| Hgb transfuse cardiac |
< 8 |
| Variceal Hgb target |
> 9 |
| UGIB EGD timing |
< 24h (active < 12h) |
| LGIB colonoscopy timing |
< 24h |
| Pantoprazole bolus |
80 mg + 8 mg/h |
| Octreotide bolus |
50 ÎŒg + 50 ÎŒg/h |
| Cirrhotic Abx |
Ceftriaxone 1g/d |
â é« yield
UGIB Etiology
- Peptic ulcer (50%)
- Varices (cirrhotic)
- Mallory-Weiss
- Erosive esophagitis / gastritis
- Dieulafoy
- Aortoenteric fistula (post-AAA repair)
- Hemobilia
LGIB Etiology
- Diverticular (most elderly)
- Angiodysplasia
- Hemorrhoids
- IBD
- Colon cancer
- Ischemic colitis
- Post-polypectomy
Glasgow-Blatchford Score
- BUN, Hgb, BP, HR, melena, syncope, cardiac/hepatic dz
- 0 = outpatient OK
- ⥠6 = high risk
Forrest Classification (peptic ulcer endoscopic)
- Ia: spurting â high rebleed
- Ib: oozing
- IIa: visible vessel
- IIb: adherent clot
- IIc: pigmented spot
- III: clean base â low rebleed
Variceal Mx
- IVF + transfuse
- Octreotide / terlipressin / vasopressin
- Ceftriaxone 1 g/d à 7 d
- EGD with band ligation (EVL) > sclerotherapy
- TIPS for refractory
- BB primary/secondary prevention
- Carvedilol > propranolol
Reverse Anticoagulation
- Warfarin: vit K + FFP / 4F-PCC
- Heparin: protamine
- Dabigatran: idarucizumab
- Apixaban / rivaroxaban: andexanet alfa or 4F-PCC
- Antiplatelet: platelet transfusion (limited evidence)
ð¯ èªææª¢æž¬
- UGIB vs LGIB anatomic? â Treitz ligament
- Cirrhotic UGIB Abx? â Ceftriaxone
- Variceal Hgb target? â > 9
- Forrest Ia? â Spurting (high rebleed)
- Heyde syndrome? â AS + colonic angiodysplasia
- Dabigatran reverse? â Idarucizumab
- UGIB EGD timing? â < 24h, active < 12h
- Diverticular bleed location? â Right > left
â ïž AI èçš¿ã